Business Wire

TX-FLUENCE

1.2.2024 14:31:34 CET | Business Wire | Press release

Share
Fluence and Innexo BV’s Research Partnership Explores Eliminating Vegetation Phase to Drive Potential Energy Savings for Growers

Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today the successful continuation of its partnership with Dutch organization Innexo BV (Innexo), a specialty agricultural contract research organization that focuses on molecular farming and medicinal plants.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240201728532/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Fluence and Innexo's partnership tests the effects of eliminating the vegetation phase for cannabis cultivation. (Photo: Business Wire)

Fluence and Innexo’s research partnership is focused on assessing the viability of cultivating cannabis without a standard vegetative phase, a practice generally associated with lower energy use that passes savings directly to growers in Europe and around the globe. Preliminary data from Fluence and Innexo demonstrates the potential of the “no-veg” growing method to help growers save money while improving quality and consistency. The Fluence and Innexo teams intend to collaborate on a full-scale research project to validate these initial results.

“At Innexo, we use our deep knowledge of cannabis cultivars and best propagation practices to help growers create the most efficient cultivation strategies possible,” said Dominique van Gruisen, managing director of Innexo. “We naturally gravitate toward partners like Fluence who can match our expertise and commitment to investing in innovative and impactful cannabis research.”

Most commercial cannabis cultivators use a vegetative phase to ensure proper plant growth to support flower weight and to gain a full and dense canopy. This phase can last anywhere between seven days and four weeks, requiring a significant investment of time, electrical energy and resources. Initial findings from Fluence and Innexo demonstrate the potential of this method to maintain crop quality and yield while creating up to 55% savings on annual electrical costs directly associated with lighting.

When the plants would typically enter the vegetative phase, they were instead transplanted to the flowering room, where they immediately received their maximum light intensity. In this system, cannabis crops reach their final height—between 70 and 120 cm—around 28 days after transplant. Eliminating two weeks of vegetative phase represents up to 252 hours of direct electricity savings per light per crop cycle. Additional savings are realized through lower HVAC costs and generally more efficient cultivation cycles. Initial research indicates that “no-veg” growing is most effective with plant densities between eight and 10 plants per m2. Thus far, research has tested the viability of “no-veg” growing across six cannabis cultivars, 10 different nutrient lines and a wide range of light intensities.

“Proper lighting—which must include a strong combination of advanced fixtures and lighting strategy—plays a critical role in creating a more efficient and profitable methodology for cannabis cultivation,” said Dr. David Hawley, principal scientist at Fluence. “This research demonstrates the value of examining and investing in a research-backed lighting strategy from day one. Our goal is to explore, validate and demonstrate the effectiveness of diverse cultivation strategies to ensure every grower can apply data-driven methodologies to their facilities in collaboration with Fluence.”

Fluence and Innexo’s research uncovered potential savings for growers who pursue growing without a vegetative phase, including an average of both 40% lower electrical costs and up to 40% lower labor costs per crop cycle. Because of the fast-paced growth of the plants, researchers found there was less time for pests and diseases to develop, leading to a healthier end product. In addition, this method could reduce waste by eliminating C-Grade flower, which allows for more crop cycles per year and increases overall predictability for growers.

“At Fluence, we create value for growers throughout the world by investing in research that will expand the horizons of traditional cultivation,” said Sebastian Olschowski, research project manager for EMEA at Fluence. "As plant lighting specialists, we are proud to be part of this project to shape the future of cannabis research and transfer valuable knowledge to our customers and partners.”

Fluence and Innexo’s research collaboration, which began in 2022, has expanded to include collaborations in three of Innexo’s Acceleration Platform for Innovation (API) programs. API empowers innovative, small-scale companies adjacent to the cannabis industry to perform research in medical cannabis cultivation.

For more information on Fluence and its ongoing global research initiatives, visit www.fluence-led.com.

About Fluence

Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis, produce and flower markets, committed to enabling more efficient crop production for the world’s top greenhouse and indoor growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Professional Business. For more information about Fluence, visit www.fluence-led.com.

About Innexo BV

Innexo BV is a specialty agricultural contract research organization (CRO) based in the Netherlands. The focus and expertise of the company are in medicinal plants, such as cannabis and molecular farming in general. Innexo BV is part of the Botany Group of companies. To learn more about Innexo BV, visit www.innexo.nl.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240201728532/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye